T. Rowe Price Associates
PRLD icon

T. Rowe Price Associates’s Prelude Therapeutics PRLD Stock Holding History

T. Rowe Price Associates’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+22,758
New +$99.1K ﹤0.01% 3115
2026
Q1 		– Sell
-755,956
Closed -$2.19M – 3182
2025
Q4 		$2.19M Sell
755,956
-120,382
-14% -$203K ﹤0.01% 1707
2025
Q3 		$1.26M Sell
876,338
-51,270
-6% -$51.4K ﹤0.01% 1957
2025
Q2 		$743K Sell
927,608
-48,539
-5% -$42K ﹤0.01% 2116
2025
Q1 		$750K Sell
976,147
-53,052
-5% -$49.5K ﹤0.01% 2087
2024
Q4 		$1.31M Sell
1,029,199
-68,400
-6% -$90.8K ﹤0.01% 1854
2024
Q3 		$2.27M Buy
1,097,599
+206,301
+23% +$955K ﹤0.01% 1573
2024
Q2 		$3.4M Sell
891,298
-50,673
-5% -$206K ﹤0.01% 1356
2024
Q1 		$4.47M Sell
941,971
-100,766
-10% -$392K ﹤0.01% 1246
2023
Q4 		$4.45M Sell
1,042,737
-24,121
-2% -$73.4K ﹤0.01% 1237
2023
Q3 		$3.3M Sell
1,066,858
-15,390
-1% -$57.7K ﹤0.01% 1297
2023
Q2 		$4.87M Buy
1,082,248
+797,886
+281% +$4.77M ﹤0.01% 1194
2023
Q1 		$1.62M Sell
284,362
-16,315
-5% -$99.5K ﹤0.01% 1547
2022
Q4 		$1.82M Sell
300,677
-12,488
-4% -$80K ﹤0.01% 1507
2022
Q3 		$2.07M Buy
313,165
+5,812
+2% +$39.2K ﹤0.01% 1441
2022
Q2 		$1.6M Sell
307,353
-15,635
-5% -$79.6K ﹤0.01% 1696
2022
Q1 		$2.23M Buy
322,988
+18,656
+6% +$171K ﹤0.01% 1656
2021
Q4 		$3.79M Sell
304,332
-90,944
-23% -$1.48M ﹤0.01% 1540
2021
Q3 		$12.4M Sell
395,276
-5,526
-1% -$179K ﹤0.01% 1401
2021
Q2 		$11.5M Sell
400,802
-22,189
-5% -$790K ﹤0.01% 1401
2021
Q1 		$18.3M Buy
422,991
+35,311
+9% +$2.34M ﹤0.01% 1294
2020
Q4 		$27.7M Sell
387,680
-12,320
-3% -$613K ﹤0.01% 1132
2020
Q3 		$12.1M Buy
+400,000
New +$11.3M ﹤0.01% 1256

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

T. Rowe Price Associates's PRLD Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 22,758 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #3115 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in PRLD as recently as Q4 2025.

T. Rowe Price Associates first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $27.7M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • T. Rowe Price Associates held 22,758 shares of Prelude Therapeutics worth $122K as of Q2 2026.
  • Prelude Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3115 holding.
  • T. Rowe Price Associates first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Prelude Therapeutics position peaked at $27.7M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.